p.91 抽出テキスト

339. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678–87. https://doi.org/10.1056/NEJMoa0800456 340. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–37. https://doi.org/10.1056/ NEJMoa043399 341. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;375:1221–30. https://doi.org/10.1056/ NEJMoa1608029 342. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–83. https:// doi.org/10.1056/NEJMoa013474 343. Beggs SAS, Jhund PS, Jackson CE, McMurray JJV, Gardner RS. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart 2018;104:144–50. https://doi.org/10. 1136/heartjnl-2016-310850 344. Shun-Shin MJ, Zheng SL, Cole GD, Howard JP, Whinnett ZI, Francis DP. Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials. Eur Heart J 2017;38: 1738–46. https://doi.org/10.1093/eurheartj/ehx028 345. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101: 1297–302. https://doi.org/10.1161/01.cir.101.11.1297 346. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 2000;21:2071–8. https://doi. org/10.1053/euhj.2000.2476 347. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576–83. https://doi.org/10.1056/NEJM199711273372202 348. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748–54. https://doi.org/10.1161/01.cir.102.7.748 349. Abdelhamid M, Rosano G, Metra M, Adamopoulos S, Bohm M, Chioncel O, et al. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention? Eur J Heart Fail 2022;24:1460–6. https://doi.org/10.1002/ ejhf.2594 350. Leyva F, Israel CW, Singh J. Declining risk of sudden cardiac death in heart failure: fact or myth? Circulation 2023;147:759–67. https://doi.org/10. 1161/CIRCULATIONAHA.122.062159 351. Rohde LE, Chatterjee NA, Vaduganathan M, Claggett B, Packer M, Desai AS, et al. Sacubitril/valsartan and sudden cardiac death according to implantable cardioverter-defibrillator use and heart failure cause: a PARADIGM-HF analysis. JACC Heart Fail 2020;8:844–55. https://doi.org/10.1016/j.jchf.2020. 06.015 352. Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, et al. Effect of the angiotensin-receptor–neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015; 36:1990–7. https://doi.org/10.1093/eurheartj/ehv186 353. Poole JE, Olshansky B, Mark DB, Anderson J, Johnson G, Hellkamp AS, et al. Long-term outcomes of implantable cardioverter-defibrillator therapy in the SCD-HeFT. J Am Coll Cardiol 2020;76:405–15. https://doi.org/10.1016/j. jacc.2020.05.061 354. Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol 2003;41: 1707–12. https://doi.org/10.1016/s0735-1097(03)00297-3 355. Elming MB, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, et al. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation 2017;136: 1772–80. https://doi.org/10.1161/CIRCULATIONAHA.117.028829 356. Hammersley DJ, Zegard A, Androulakis E, Jones RE, Okafor O, Hatipoglu S, et al. Arrhythmic risk stratification by cardiovascular magnetic resonance imaging in patients with nonischemic cardiomyopathy. J Am Coll Cardiol 2024; 84:1407–20. https://doi.org/10.1016/j.jacc.2024.06.046 357. Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC Heart Fail 2017;5:28–38. https://doi.org/10.1016/j.jchf.2016.09.017 358. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481–8. https://doi.org/10.1056/ NEJMoa041489 359. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009;361:1427–36. https://doi.org/10.1056/NEJMoa0901889 360. DeFilippis EM, Butler J, Vaduganathan M. Waiting period before implantable cardioverter-defibrillator implantation in newly diagnosed heart failure with reduced ejection fraction: a window of opportunity. Circ Heart Fail 2017;10: e004478. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004478 361. Ruwald MH, Ruwald AC, Johansen JB, Gislason G, Nielsen JC, Philbert B, et al. Incidence of appropriate implantable cardioverter-defibrillator therapy and mortality after implantable cardioverter-defibrillator generator replacement: results from a real-world nationwide cohort. Europace 2019;21:1211–9. https://doi.org/10.1093/europace/euz121 362. Ruwald MH, Solomon SD, Foster E, Kutyifa V, Ruwald AC, Sherazi S, et al. Left ventricular ejection fraction normalization in cardiac resynchronization therapy and risk of ventricular arrhythmias and clinical outcomes: results from the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) trial. Circulation 2014;130: 2278–86. https://doi.org/10.1161/CIRCULATIONAHA.114.011283 363. Steffel J, Milosevic G, Hurlimann A, Krasniqi N, Namdar M, Ruschitzka F, et al. Characteristics and long-term outcome of echocardiographic superresponders to cardiac resynchronisation therapy: ‘real world’ experience from a single tertiary care centre. Heart 2011;97:1668–74. https://doi.org/ 10.1136/heartjnl-2011-300222 364. Lee KS, Oh O, Miller J, Hammash M, Thompson DR, Ski CF, et al. Patients’ openness to discussing implantable cardioverter defibrillator deactivation at end of life: a cross-sectional study. Eur J Cardiovasc Nurs 2022;21: 687–93. https://doi.org/10.1093/eurjcn/zvab130 365. Trussler A, Alexander B, Campbell D, Alhammad N, Enriquez A, Chacko S, et al. Deactivation of implantable cardioverter defibrillator in patients with terminal diagnoses. Am J Cardiol 2019;124:1064–8. https://doi.org/10. 1016/j.amjcard.2019.07.007 366. Kobza R, Erne P. End-of-life decisions in ICD patients with malignant tumors. Pacing Clin Electrophysiol 2007;30:845–9. https://doi.org/10.1111/j.1540- 8159.2007.00771.x 367. Keene D, Nielsen JC, Burri H, Chavez-Gutierrez CA, Deharo JC, Drossart I, et al. Cardiac implantable electronic device upgrades and downgrades: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Asia Pacific Heart Rhythm Association (APHRS), Canadian Heart Rhythm Society (CHRS), Heart Rhythm Society (HRS), and the Latin American Heart Rhythm Society (LAHRS). Europace 2025;27:euaf252. https://doi.org/10.1093/europace/euaf252 368. Knops RE, Olde Nordkamp LRA, Delnoy PHM, Boersma LVA, Kuschyk J, El-Chami MF, et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med 2020;383:526–36. https://doi.org/10.1056/NEJMoa1915932 369. Burke MC, Gold MR, Knight BP, Barr CS, Theuns D, Boersma LVA, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS registry. J Am Coll Cardiol 2015;65:1605–15. https://doi.org/10.1016/j. jacc.2015.02.047 370. Friedman P, Murgatroyd F, Boersma LVA, Manlucu J, O’Donnell D, Knight BP, et al. Efficacy and safety of an extravascular implantable cardioverterdefibrillator. N Engl J Med 2022;387:1292–302. https://doi.org/10.1056/ NEJMoa2206485 371. Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, et al. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med 2018;379:1205–15. https://doi.org/10.1056/NEJMoa1800781 372. Veltmann C, Duncker D, Doering M, Gummadi S, Robertson M, Wittlinger T, et al. Therapy duration and improvement of ventricular function in de novo heart failure: the Heart Failure Optimization study. Eur Heart J 2024;45: 2771–81. https://doi.org/10.1093/eurheartj/ehae334 373. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335: 1933–40. https://doi.org/10.1056/NEJM199612263352601 374. Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, et al. Survival benefit of the primary prevention implantable cardioverterdefibrillator among older patients: does age matter? An analysis of pooled Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026